Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial

G Roberts, D Newsom, K Gomez, A Raffles, S Saglani, J Begent, P Lachman, K Sloper, R Buchdahl, A Habel on behalf of the North West Thames Asthma Study Group

Background: The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear. A single bolus of salbutamol was compared with a continuous aminophylline infusion in children with severe asthma in a randomised double blind study.

Methods: Children aged 1–16 years with acute severe asthma were enrolled if they showed little improvement with three nebulisers (combined salbutamol and ipratropium) administered over an hour and systemic steroids. Subjects were randomised to receive either a short intravenous bolus of salbutamol (15 µg/kg over 20 minutes) followed by a saline infusion or an aminophylline infusion (5 mg/kg over 20 minutes) followed by 0.9 mg/kg/h.

Results: Forty four subjects were enrolled, with 18 randomly allocated to receive salbutamol and 26 to receive aminophylline. The groups were well matched at baseline. An intention to treat analysis showed that there was no statistically significant difference in the asthma severity score (ASS) at 2 hours between the two groups (median [IQR] 6 [6, 8] and 6.5 [5, 8] for salbutamol and aminophylline respectively, p=0.93). A similar improvement in ASS to 2 hours was seen in the two groups (mean difference –0.08, 95% CI –0.97 to 0.80), there was a trend (p=0.07) towards a longer duration of oxygen therapy in the salbutamol group (17.8 hours (95% CI 8.5 to 37.5) v 7.0 hours (95% CI 3.4 to 14.2)), and a significantly (p=0.02) longer length of hospital stay in the salbutamol group (85.4 (95% CI 66.1 to 110.2) hours v 57.3 hours (95% CI 45.6 to 72.0)). There was no significant difference in adverse events between the two groups.

Conclusions: This study suggests that, in severe childhood asthma, there is no significant difference in the effectiveness of a bolus of salbutamol and an aminophylline infusion in the first 2 hours of treatment. Overall, the aminophylline infusion was superior as it significantly reduced the length of stay in hospital.

The consensus treatment for severe acute exacerbations of asthma is a combination of nebulised β agonist and ipratropium with oral corticosteroids. There is controversy as to whether aminophylline or a β agonist such as salbutamol is the most effective first line intravenous bronchodilator for the optimal management of a child who does not improve. Many British paediatricians consider that aminophylline is the drug of choice, despite the limited evidence for its efficacy and significant adverse effects. Intravenous salbutamol has a better safety profile and has been shown to reduce the severity and duration of severe acute asthma in children. More recently it has also been shown in two studies that salbutamol is effective in acute severe asthma when given as a short bolus in combination with continuous nebulised salbutamol. One hypothesis for this benefit is that intravenous salbutamol reaches airways obstructed by the bronchospasm, oedema and mucus associated with a severe exacerbation of asthma; once opened, nebulised agents may then reach these airways. Intravenous salbutamol and aminophylline have not been compared in a study of sufficient size to detect differences in their effectiveness. In this study we compare the effectiveness of a short bolus of salbutamol with an aminophylline infusion in children and teenagers with severe asthma using a randomised double blind design.

METHODS

Study population
Subjects were recruited between 1999 and 2001 from five district general hospitals in the North West Thames region (West Middlesex University Hospital, Queen Elizabeth II Hospital, Northwick Park Hospital, Ealing Hospital, and Hillingdon Hospital). Subjects were included if they were aged 1–16 years and had presented with acute severe asthma that had responded poorly to three nebulisers containing salbutamol (2.5 mg, 3 mg if ≥ 5 years) and ipratropium (125 µg, 250 µg if ≥ 5 years) over a 1 hour period. Asthma was diagnosed on the basis of clinical history and examination. A score of 7 or more on the 9-point asthma severity score (ASS) indicated a severe exacerbation. A poor response was defined as an improvement in the ASS of <2; an ASS after three doses of nebulised treatment of ≥7; or a continuing requirement for supplementary oxygen to maintain saturations of at least 92% (Ohmeda 3800 pulse oximeter). Subjects were excluded if they had a life threatening exacerbation, an underlying respiratory disease other than asthma, cardiac disease, or treatment with a medication that alters the metabolism of aminophylline.

Written consent was obtained from all families and the study was approved by the Thames Multicentre Research ethics committee and the local ethics committees.

Intervention
Subjects were treated with either a single bolus of intravenous salbutamol (15 µg/kg over 20 minutes) followed by an infusion of saline or a continuous aminophylline infusion (bolus of 5 mg/kg over 20 minutes followed by an infusion of 0.9 mg/kg/h). Visibly identical numbered treatment packs were made by the pharmacy department at West Middlesex Hospital.

Thorax 2003;58:306–310

See end of article for authors’ affiliations

Correspondence to:
Dr G Roberts, Paediatric Respiratory Medicine, Royal London Hospital, London E1 1BB; g.c.roberts@ic.ac.uk

Accepted for publication 2 December 2002
Revised version received 16 December 2002
Intravenous salbutamol bolus v aminophylline infusion in severe paediatric asthma 307

Figure 1 Subject flow sheet.

University Hospital. Study numbers were assigned to aminophylline or salbutamol according to a random number table. Each centre had its own sequence of numbers to ensure that each enrolled similar numbers into each group. Subjects were treated with the next serially numbered treatment pack. Only one investigator (GR), who had no involvement in the enrolment or clinical care of any subject, was aware of this allocation. Blood was taken 1 hour after starting intravenous therapy for measurement of potassium and aminophylline levels. The drug levels were assayed centrally and checked by one investigator (GR). If the drug level was outside the range 7–15 mg/l, the clinicians were instructed to adjust the infusion rate. For subjects in the salbutamol arm, the clinicians were given instructions to maintain, increase, or reduce the rate at random to maintain blinding. All subjects were also treated with systemic corticosteroids, nebulised salbutamol as required, and 6 hourly nebulised ipratropium. Nebulised and intravenous treatment was reduced according to a plan to stop the study if the primary end point reached statistical significance at a level of <0.001 (Peto method). This criterion was not reached. The other investigators were blind to this interim analysis. A level of 5% was taken as significant for this because of their age or the severity of the exacerbation. Adverse effects were recorded. All outcome measures were recorded by staff who were unaware of the subject's allocation.

Statistical methods
An intention to treat analysis was undertaken. The ASS in each group after 2 hours of treatment was compared using a Wilcoxon rank sum test (early primary end point). The change in the ASS from baseline to 2 hours was normally distributed; this parameter was compared between the two groups to provide a comparison that included a confidence interval. The duration of supplemental oxygen therapy (late primary end point) and the time to discharge (secondary end point) in each group were compared using an unpaired t test. In addition, the percentage of subjects experiencing an adverse event in each group was compared using a χ² or Fisher’s exact test, as appropriate (secondary end point) and the serum potassium level before and after the bolus was compared using a t test. It was calculated that the data from 42 subjects would be sufficient to detect a 30% difference in change in severity score at 2 hours between the two groups assuming a standard deviation of 30% of the ASS, 90% power, and a 5% level of significance. An interim analysis was undertaken by one investigator (GR) after 21 subjects had been randomised, with a plan to stop the study if the primary end point reached statistical significance at a level of <0.001 (Peto method). This criterion was not reached. The other investigators were blind to this interim analysis. A level of 5% was taken as significant.
Subjects and treatment allocation
Sixty children were admitted with severe asthma during a cumulative recruitment period of 97 months at the five hospitals, 44 of whom were enrolled into the study (fig 1). Eighteen subjects (40.9%) were randomly allocated to treatment with a bolus of salbutamol and 26 (59.1%) to an aminophylline infusion. There were no significant differences in the baseline demographic characteristics of these subjects, in their previous asthma history or presenting exacerbation (table 1). There were three early withdrawals; one from the aminophylline group who refused to allow a cannula to be inserted and two in the salbutamol group who were temporarily stopped and restarted at a lower rate.

Asthma severity score
Using an intention to treat analysis, there were no significant differences in the ASS for each group either before the commencement of the intravenous bronchodilator or in the following 24 hours (table 2, fig 2). The difference in the change in ASS between the aminophylline and salbutamol groups was –0.08 (95% CI –0.97 to 0.80), table 2. This result was unchanged when the early withdrawals were excluded.

Supplementary oxygen
There was no difference in the proportions requiring supplementary oxygen or the saturation in air before intravenous treatment (table 2) or at any time in the subsequent 24 hours (fig 3). Subjects in the aminophylline and salbutamol groups required supplementary oxygen for 7.0 hours (95% CI 3.4 to 14.2) and 17.8 hours (8.5 to 37.5), respectively (table 2). The salbutamol group therefore required supplementary oxygen for 2.56 times longer (95% CI 0.92 to 7.18) using an intention to treat analysis. Exclusion of the early withdrawals from the analysis did not change the result.

Additional therapy
The intravenous study medication ran for similar lengths of time in the salbutamol and aminophylline groups (table 2). The use of nebulised salbutamol was also similar in the two groups with at least hourly treatment for the first 6 hours.

for the final analysis. All statistical tests were undertaken using Stata 6.

RESULTS

Table 1 Baseline characteristics of study subjects

<table>
<thead>
<tr>
<th>Item</th>
<th>Salbutamol (n=18)</th>
<th>Aminophylline (n=26)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F (% males)</td>
<td>12:6 (66.7%)</td>
<td>20:6 (76.9%)</td>
<td>0.45</td>
</tr>
<tr>
<td>Age (years)</td>
<td>3.85 (1.35, 15.55)</td>
<td>4.12 (1.19, 13.13)</td>
<td>0.80</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>15.0 (12.0, 30.4)</td>
<td>16.8 (12.5, 30.0)</td>
<td>0.83</td>
</tr>
<tr>
<td>Age at which asthma diagnosed (years)</td>
<td>2.00 (1.00, 2.75)</td>
<td>1.25 (1.00, 2.75)</td>
<td>0.63</td>
</tr>
<tr>
<td>No of previous admissions with asthma</td>
<td>1 (0, 2)</td>
<td>1 (0, 6)</td>
<td>0.54</td>
</tr>
<tr>
<td>Previous intravenous therapy for asthma</td>
<td>4 (22.2%)</td>
<td>4 (15.4%)</td>
<td>0.70</td>
</tr>
<tr>
<td>Previous ventilatory support for asthma</td>
<td>1 (0, 5)</td>
<td>1 (0, 3)</td>
<td>1.00</td>
</tr>
<tr>
<td>No with eczema</td>
<td>8 (88.8%)</td>
<td>8 (72.7%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Duration of exacerbation (hours)</td>
<td>24 (24, 72)</td>
<td>24 (24, 48)</td>
<td>0.56</td>
</tr>
<tr>
<td>Treatment with nebulised β agonists before presentation</td>
<td>2 (11.8%)</td>
<td>5 (20.0%)</td>
<td>0.68</td>
</tr>
<tr>
<td>Duration of treatment with systemic corticosteroids pre-study bolus (hours)</td>
<td>3.0 (0.5, 10.9)</td>
<td>3.0 (0.0, 3.5)</td>
<td>0.96</td>
</tr>
<tr>
<td>ASS on admission</td>
<td>8 (6, 9)</td>
<td>9 (7, 9)</td>
<td>0.45</td>
</tr>
<tr>
<td>ASS at start of study bolus</td>
<td>8 (7, 8)</td>
<td>8 (7, 9)</td>
<td>0.76</td>
</tr>
<tr>
<td>Saturation in air on admission</td>
<td>87.5% (&lt;84.0, 91.0)</td>
<td>90.0% (87.0, 94.0)</td>
<td>0.28</td>
</tr>
<tr>
<td>Saturation in air at start of study bolus</td>
<td>91.0% (88.5, 93.5)</td>
<td>91.0% (88.0, 93.0)</td>
<td>0.77</td>
</tr>
<tr>
<td>Need for supplementary oxygen at start of trial bolus</td>
<td>14 (77.8%)</td>
<td>19 (99.2%)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

Values are medians with interquartile ranges or proportions with percentages.
*Comparison of subjects in each group: medians compared with Wilcoxon rank sum test; proportions compared with χ² or Fisher’s exact test as appropriate.

Table 2 Progress of study subjects

<table>
<thead>
<tr>
<th>Item</th>
<th>Salbutamol (n=18)</th>
<th>Aminophylline (n=26)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma severity score (ASS) at 2 hours</td>
<td>6 (0.37)</td>
<td>6.5 (0.33)</td>
<td>0.93</td>
</tr>
<tr>
<td>Change in ASS from time 0 to 2 hours</td>
<td>–1.11 (0.39)</td>
<td>–1.19 (0.25)</td>
<td>0.95</td>
</tr>
<tr>
<td>Duration of oxygen therapy (hours)</td>
<td>17.8 (8.9)</td>
<td>7.6 (6.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>Duration of infusion (hours)</td>
<td>32.2 (3.2)</td>
<td>27.8 (0.85)</td>
<td>0.41</td>
</tr>
<tr>
<td>Time to discharge (hours)</td>
<td>85.4 (13.2)</td>
<td>57.3 (8.5)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Values for the salbutamol and aminophylline groups are presented with standard errors (SE).
*Comparison of subjects in each group using unpaired t test (change in ASS, duration of oxygen and infusion, and time to discharge) or Wilcoxon rank sum test (ASS at 2 hours).
All subjects included in the intention to treat analysis.

Figure 2. Asthma severity scores in the salbutamol (dotted line) and aminophylline (continuous line) groups. Values are plotted as medians with interquartile ranges.
In this study we have compared an intravenous bolus of salbutamol with an infusion of aminophylline in a population of children with severe acute asthma that was unresponsive to maximal nebulised treatment and systemic corticosteroids. The results show that there was no statistically significant difference in the effectiveness of these two regimes after 2 hours, although overall the aminophylline infusion appeared superior as it reduced the length of stay in hospital.

A recent Cochrane review compared aminophylline with placebo in children with severe acute asthma receiving treatment with inhaled bronchodilators and systemic glucocorticoids. It showed that aminophylline improves lung function, reduces clinical severity, and reduces the need for ventilation. This is contrary to the results of a previous meta-analysis of adult studies. The largest study included in the Cochrane review was by Yung et al which contributed 163 of the 380 cases and was the only one to show a measurable benefit. Like the study by Yung et al, our investigation enrolled subjects only if they had a severe exacerbation of asthma. This suggests that subjects with less severe exacerbations improve regardless of whether they receive additional intravenous treatment, and that the relatively small improvement in lung function produced by an aminophylline infusion is therefore only beneficial to children with the most severe exacerbations. The study presented here also showed that the group receiving aminophylline had a 30% shorter stay in hospital. This has significant implications for health service resources as well as the child's well being, given that an aminophylline infusion appears to shorten the admission time by more than a day.

A second Cochrane review which examined the addition of intravenous salbutamol in severe acute asthma in adults and children found that it imparted no additional benefit for those requiring an intravenous treatment and placebo. These conclusions are flawed for a number of reasons; 80% of the included studies were published before 1990 when lower doses of intravenous β₂ agonists were used compared with those currently in use. The review states that there are insufficient paediatric studies to provide subgroup comparisons. This is important as children with asthma behave differently from adults as atopy is a more common feature and they do not have concurrent chronic obstructive airway disease or ischaemic heart disease. All but one of the studies in the Cochrane review used suboptimal concurrent nebulised therapy. The two adequately sized randomised controlled trials in children show that intravenous salbutamol is effective. Brown et al enrolled subjects who failed to improve after one dose of nebulised salbutamol. A bolus of intravenous salbutamol or placebo was followed by frequent nebulised therapy. A significant improvement in the ASS occurred within 2 hours, together with earlier discharge from hospital. Intravenous salbutamol may be able to reach the obstructed airways seen in severe exacerbations of asthma, thereby allowing nebulised agents to reach them.

Intravenous aminophylline and β₂ agonist have only ever been compared in severe acute childhood asthma in one study. This study used very small intravenous dosages, gave no concurrent nebulised therapy, and enrolled insufficient subjects to detect anything but a major difference. The adult studies addressing this issue are similarly flawed. Using the currently recommended intravenous dosages and frequency of concurrent nebulised therapy, we have shown that an aminophylline infusion is more effective than a single bolus of salbutamol. Only three quarters of the salbutamol group recovered with a single bolus, which is disappointing as a bolus of salbutamol is an attractive option for the busy paediatric emergency department. The subjects enrolled into the study by Browne et al had only been treated with one dose of nebulised salbutamol whereas our patients had failed to improve with three doses of nebulised salbutamol and ipratropium. It is therefore perhaps not surprising that, unlike Browne et al, we failed to show that a single bolus of salbutamol was more effective than aminophylline. It is possible, however, that a proportion of these non-responders would have improved after a further bolus or a continuous infusion of salbutamol.

This study has several limitations. It is relatively small, although we were still able to demonstrate equivalence after 2 hours and a significant difference in duration of admission. The 95% confidence interval for the difference in improvement in ASS to 2 hours between the two groups was −0.97 to 0.80. Given that the ASS is a 9 point scoring system, the difference in efficacy between the two treatments is minimal within this time frame. A larger study would have enabled a comparison of other important outcome measures such as the need for mechanical ventilation, although with only 11% and 4% requiring ventilation in the salbutamol and aminophylline groups, respectively, a few hundred subjects would have had to be enrolled to address this issue successfully. Although there was an imbalance in the allocation between the two groups, this did not adversely reduce the statistical power of the study.
We included subjects who satisfied the clinical severity score, regardless of whether or not they required supplementary oxygen. This reduced the number of subjects available to determine the relative length of supplementary oxygen therapy, which probably prevented this end point reaching significance. Aminophylline levels were only assayed after 1 hour of treatment when many of the subjects had levels below the quoted therapeutic range. They had, however, received the standard aminophylline loading dose. It is perhaps significant that the two studies which showed that aminophylline is effective used a higher bolus dose. However, we have shown that an infusion of aminophylline is more effective than a bolus of salbutamol. As we did not provide a protocol for treating subjects who failed to improve with the study medication, we were unable to examine systematically the role of adding the other bronchodilator or additional agents such as magnesium sulphate.

The consensus for treating severe acute asthma is currently moving from intravenous aminophylline towards intravenous β₂ agonist. This is despite the paucity of randomised controlled trials incorporating current dosages of intravenous bronchodilators and frequent nebulised therapy in the paediatric age group. This study is helpful in informing the debate on the relative merits of intravenous salbutamol and aminophylline and whether salbutamol should be used as a bolus or infusion. It shows that there is no statistically significant difference in the effectiveness of intravenous salbutamol and aminophylline over the first 2 hours of treatment. Overall, the infusion of aminophylline was more effective with a significant reduction in the duration of admission and a trend towards a shorter duration of supplementary oxygen. Adverse effects did not appear to be significantly greater in the aminophylline group. Further clinical studies are required to determine whether multiple intravenous boluses of salbutamol are as effective as an aminophylline infusion, to evaluate the relative effectiveness of infusions of salbutamol and aminophylline, and to investigate whether these two intravenous bronchodilators are synergistic in acute severe asthma.

ACKNOWLEDGEMENTS

The authors acknowledge the help of all the staff working at the five hospitals involved, particularly Andrea Thomas, Pippa Banister; Mitch Blair, Wouter Hanekom, Keith Brent, Nittha Naqvi, Julian Redhead, Keela Taylor and Ranjan Suri; the statistical advice provided by Paul Bassett; and all the children and families involved without whom the study would not have been possible.

Authors’ affiliations

G Roberts, Imperial College School of Medicine at St Mary’s Hospital, London, UK
G Roberts, K Gomez, A Habel, West Middlesex Hospital
D Newsom, P Lachman, Northwick Park Hospital
A Raffles, S Sogiani, J Begent, Queen Elizabeth II Hospital
K Sloper, Ealing Hospital
R Buchdahl, Hillingdon Hospital

DN had the original idea for the study. The protocol was developed by GR, DN and AH. All the authors were involved in entering subjects into the study and collecting data. GR undertook the data analysis and wrote the first draft of the paper. All the authors contributed to the revision of the paper. AH will act as guarantor of the paper.

This work was supported by funding from the NHS London Regional Office, Research & Development Programme. The views expressed in the publication are those of the authors and not necessarily of the NHS or the Department of Health.

REFERENCES